Casdin Capital, LLC
Filing Date
Global Rank
#1,516
/ 8,623
▼ 106
· as of Mar 2026
Top Industry
Biotechnology
53.4%
3Y Alpha vs SPY
-0.2%
Period ended 4 months ago
Filed May 15, 2026 · 3mo
25 quarters · since Mar 2020
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
+67.1%
SPY
+65.3%
Annualised alpha
+0.4%
Max drawdown
−39.3%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. It tracks 100% of reported value on average across 13 quarters. Past performance does not predict future results.
Portfolio Concentration
40 tracked positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
19.0%
−6.5 pts
Top 5
59.3%
−3.4 pts
Top 10
77.3%
−3.3 pts
HHI
903
Diversified−212
Portfolio Trend
25 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $1,320,653,767 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
7 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc. | +1,750,000 | 3,250,000 | $14,527,500 | |
| RLAY | Relay Therapeutics, Inc. | +1,415,000 | 14,418,574 | $143,464,811 | |
| TXG | 10x Genomics, Inc. | +875,000 | 2,275,000 | $48,298,250 | |
| HIMS | Hims & Hers Health, Inc. | +315,000 | 700,000 | $14,532,000 | |
| NGNE | Neurogene Inc. | +125,000 | 1,420,361 | $28,634,477 | |
| GLUE | Monte Rosa Therapeutics, Inc. | +100,000 | 186,014 | $3,059,930 | |
| SRRK | Scholar Rock Holding Corp | +90,000 | 350,000 | $17,206,000 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
4 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| PACB | Pacific Biosciences Of California, Inc. | −3,500,000 | 723,767 | $955,372 | |
| BEAM | Beam Therapeutics Inc. | −250,000 | 1,350,000 | $32,170,500 | |
| ILMN | Illumina, Inc. | −70,000 | 530,000 | $65,327,800 | |
| GH | Guardant Health, Inc. | −65,000 | 315,000 | $29,096,550 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
9 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| AGMB | Agomab Therapeutics NV | 1,550,000 | $16,259,500 | |
| QGEN | Qiagen N.V. | 360,000 | $14,414,400 | |
| GRAL | GRAIL, Inc. | 230,000 | $11,886,400 | |
| PSNL | Personalis, Inc. | 1,600,000 | $10,192,000 | |
| MLTX | MoonLake Immunotherapeutics | 450,000 | $8,388,000 | |
| NTLA | Intellia Therapeutics, Inc. | 355,000 | $4,551,100 | |
| IRON | Disc Medicine, Inc. | 65,000 | $4,156,100 | |
| MRNA | Moderna, Inc. | 75,000 | $3,810,000 | |
| ANL | Adlai Nortye Ltd. | 538,461 | $3,726,150 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
6 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc. | 1,600,000 | $18,640,000 | |
| UNH | Unitedhealth Group Inc | 50,000 | $16,505,500 | |
| DXCM | Dexcom Inc | 175,000 | $11,614,750 | |
| CI | Cigna Group | 40,000 | $11,009,200 | |
| INCY | Incyte Corp | 100,000 | $9,877,000 | |
| LEGN | Legend Biotech Corp | 215,000 | $4,674,100 | |
| No positions match the current search. | ||||
40 tracked positions ·
$1,320,653,767 total
· filing declares
40 positions · $1,320,591,769
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Held | 2,577,333 | $250,645,634 | 18.98% | |
| WGS |
GeneDx Holdings Corp.
Healthcare
|
Held | 3,007,164 | $193,120,072 | 14.62% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Reduced | 14,418,574 | $143,464,811 | 10.86% | |
| BLFS |
Biolife Solutions Inc
Healthcare
|
Held | 5,957,165 | $113,662,708 | 8.61% | |
| LAB |
Standard Biotools Inc.
Healthcare
|
Held | 88,783,856 | $81,681,147 | 6.18% | |
| ILMN |
Illumina, Inc.
Healthcare
|
Reduced | 530,000 | $65,327,800 | 4.95% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Held | 1,175,000 | $56,635,000 | 4.29% | |
| TXG |
10x Genomics, Inc.
Healthcare
|
Added | 2,275,000 | $48,298,250 | 3.66% | |
| DNLI |
Denali Therapeutics Inc.
Healthcare
|
Held | 1,840,000 | $35,328,000 | 2.68% | |
| BEAM |
Beam Therapeutics Inc.
Healthcare
|
Reduced | 1,350,000 | $32,170,500 | 2.44% | |
| GH |
Guardant Health, Inc.
Healthcare
|
Reduced | 315,000 | $29,096,550 | 2.20% | |
| NGNE |
Neurogene Inc.
Healthcare
|
Added | 1,420,361 | $28,634,477 | 2.17% | |
| ALNY |
Alnylam Pharmaceuticals, Inc.
Healthcare
|
Held | 75,000 | $24,815,250 | 1.88% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Held | 758,857 | $22,651,881 | 1.72% | |
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
Added | 350,000 | $17,206,000 | 1.30% | |
| AGMB |
Agomab Therapeutics NV
Healthcare
|
NEW | 1,550,000 | $16,259,500 | 1.23% | |
| HIMS |
Hims & Hers Health, Inc.
Healthcare
|
Added | 700,000 | $14,532,000 | 1.10% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Added | 3,250,000 | $14,527,500 | 1.10% | |
| QGEN |
Qiagen N.V.
Healthcare
|
NEW | 360,000 | $14,414,400 | 1.09% | |
| TEM |
Tempus AI, Inc.
Healthcare
|
Held | 294,127 | $13,300,422 | 1.01% | |
| SEPN |
Septerna, Inc.
Healthcare
|
Held | 553,268 | $13,295,030 | 1.01% | |
| GRAL |
GRAIL, Inc.
Healthcare
|
NEW | 230,000 | $11,886,400 | 0.90% | |
| PRME |
Prime Medicine, Inc.
Healthcare
|
Held | 3,167,175 | $11,021,769 | 0.83% | |
| PSNL |
Personalis, Inc.
Healthcare
|
NEW | 1,600,000 | $10,192,000 | 0.77% | |
| DGX |
Quest Diagnostics Inc
Healthcare
|
Held | 50,000 | $9,799,000 | 0.74% | |
| VCYT |
Veracyte, Inc.
Healthcare
|
Held | 276,308 | $8,899,880 | 0.67% | |
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
NEW | 450,000 | $8,388,000 | 0.64% | |
| NTLA |
Intellia Therapeutics, Inc.
Healthcare
|
NEW | 355,000 | $4,551,100 | 0.34% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
NEW | 65,000 | $4,156,100 | 0.31% | |
| MRNA |
Moderna, Inc.
Healthcare
|
NEW | 75,000 | $3,810,000 | 0.29% | |
| ANL |
Adlai Nortye Ltd.
Healthcare
|
NEW | 538,461 | $3,726,150 | 0.28% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Added | 186,014 | $3,059,930 | 0.23% | |
| ABSI |
Absci Corp
Healthcare
|
Held | 973,260 | $2,919,780 | 0.22% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Held | 1,228,190 | $2,775,709 | 0.21% | |
| BBOT |
BridgeBio Oncology Therapeutics, Inc.
Healthcare
|
Held | 282,312 | $2,526,692 | 0.19% | |
| CTNM |
Contineum Therapeutics, Inc.
Healthcare
|
Held | 148,333 | $1,937,228 | 0.15% | |
| PACB |
Pacific Biosciences Of California, Inc.
Healthcare
|
Reduced | 723,767 | $955,372 | 0.07% | |
| RXRX |
Recursion Pharmaceuticals, Inc.
Healthcare
|
Held | 165,323 | $507,541 | 0.04% | |
| TNYA |
Tenaya Therapeutics, Inc.
Healthcare
|
Held | 361,969 | $250,482 | 0.02% | |
| DNA |
Ginkgo Bioworks Holdings, Inc.
Healthcare
|
Held | 36,493 | $223,702 | 0.02% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.